IP Library Granted Patent US 10,286,006
Granted Patent B2
US 10,286,006 · App. 15/165,773 · Granted May 14, 2019

Trace elements

Inventors: Robert N. Laurie (Somerset West, ZA); William A. Smith (Dublin, IE)
Assignee: WARBURTON TECHNOLOGY LIMITED
A61K33/34A61K9/0019A61K9/08A61K31/00A61K31/095A61K31/167A61K31/365A61K31/4184A61K31/429A61K31/565A61K31/568A61K31/57A61K31/7048A61K33/00A61K33/04A61K33/18A61K33/24A61K33/26A61K33/30A61K33/32A61K39/00A61K45/06A61K47/10A61K47/183
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,286,006
App. No.
15/165,773
Granted
May 14, 2019
Kind
B2
Abstract

A trace element solution comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronization preparation. The synchronization preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation. The antibiotics include oral, injectable and implantable therapeutic remedies. The vaccine includes antigens and a combination of antigens and adjuvants. The growth stimulants include zeranol, estradiol, testosterone, progesterone and trenbolone acetate. The dewormer includes macrocyclic lactones, leramizoles, benzimidazoles and salicylanilides. The macrocyclic lactones include doramectin, ivermectin, abamectin and moxidectin.

Claims (22)

1. An injectable trace element solution, produced from:

(a) a first solution comprising selenium and metals zinc and manganese, wherein at least one of the metals is in the form of a complex with EDTA, the EDTA being selected from the group consisting of sodium EDTA, sodium hydroxide EDTA acid and potassium EDTA, and at least one addition metal selected from the group consisting of copper, chromium and iron, wherein the total concentration of selenium, zinc, manganese and said at least one additional metal is greater than 60 mg/ml;

(b) a second solution comprising a dewormer and at least one other component selected from the group consisting of a vitamin, a vaccine, a growth stimulant, iron dextran, an antibiotic and a hormonal synchronization preparation; and

(c) chlorocresol as a preservative;

wherein injectable trace element solution is produced by combining the first solution and the second solution;

wherein the first solution is produced in part by adding Na 2 SeO 3 and MnSO 4 ;

wherein the injectable trace element solution has a total concentration of selenium, zinc, manganese and said at least one additional metal of at least 60 mg/ml; and

wherein the antibiotic has efficiency to treat or limit the occurrence of infection diseases.

2. The injectable trace element solution as claimed in claim 1 , wherein the vaccine includes at least one compound selected from the group consisting of antigens and a combination of antigens and adjuvants.

3. The injectable trace element solution as claimed in claim 1 , wherein the growth stimulants include at least one compound selected from the group consisting of zeranol, estradiol, testosterone, progesterone and trenbolone acetate.

4. The injectable trace element solution as claimed in claim 1 , wherein the dewormer includes at least one compound selected from the group consisting of macrocyclic lactones, levamisole, benzimidazoles and salicylanilides.

5. The injectable trace element solution as claimed in claim 4 , wherein the macrocyclic lactones include at least one compound selected from the group consisting of doramectin, ivermectin, abamectin and moxidectin.

6. The injectable trace element solution of claim 1 , wherein its pH is between 6.7 and 7.0 inclusive.

7. A method for limiting the occurrence of a disease or disease condition or treating a disease condition selected from the group consisting of deficiency or suboptimal level of trace elements, infectious disease treatable by an antibiotic, parasitic worm infections, and vitamin deficiency, said method comprising administering to a patient in need of treatment therefrom, a therapeutically effective amount of an injectable trace element solution, the injectable trace element solution comprising:

(a) a first solution comprising selenium and metals zinc and manganese, wherein at least one of the metals is in the form of a complex with EDTA, the EDTA being selected from the group consisting of sodium EDTA, sodium hydroxide EDTA acid and potassium EDTA, and at least one addition metal selected from the group consisting of copper, chromium and iron, wherein the total concentration of selenium, zinc, manganese and said at least one additional metal is greater than 60 mg/ml;

(b) a second solution comprising a dewormer and at least one other component selected from the group consisting of a vitamin, a vaccine, a growth stimulant, iron dextran, an antibiotic and a hormonal synchronization preparation; and

(c) chlorocresol as a preservative;

wherein injectable trace element solution is produced by combining the first solution and the second solution;

wherein the first solution is produced in part by adding Na 2 SeO 3 and MnSO 4 ;

wherein the injectable trace element solution has a total concentration of selenium, zinc, manganese and said at least one additional metal of at least 60 mg/ml; and

wherein the antibiotic has efficiency to treat or limit the occurrence of infection diseases.

8. The method of claim 7 , wherein the disease condition is an infectious disease.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (AS SUCCESSOR IN INTEREST TO U.S. BANK NATIONAL ASSOCIATION), AS ADMINISTRATIVE AGENT
To: AXIOTA U.S., INC. (F/K/A MS BIOTECH, INC.); WARBURTON TECHNOLOGY LIMITED
Reel/Frame 073791/0089 →
ASSIGNMENT AND ASSUMPTION AGREEMENT Recorded Mar 17, 2023
From: U.S. BANK NATIONAL ASSOCIATION
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 063115/0486 →
SECURITY INTEREST Recorded Dec 24, 2019
From: WARBURTON TECHNOLOGY LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051363/0001 →
Priority Claims (1)
ZA 2004/7201 · Sep 9, 2004 · national
Continuity (3)
Continuation 13759454 · Feb 5, 2013
Division 11574692
Related Publication 20160271176A1 · Sep 22, 2016